Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Wellington Management disclosed beneficial ownership of 20,627,307 shares of Structure Therapeutics common stock, representing 11.95% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 19,646,661 and shared dispositive power of 20,627,307, indicating these securities are managed jointly across Wellington entities. The shares are owned of record by clients of Wellington Investment Advisers rather than by Wellington as principal.
The filing also states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. One named client, Vanguard Health Care Fund, is identified as an exception to the general statement about clients.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.